Clinical Trials Directory

Trials / Unknown

UnknownNCT01467960

Apolipoprotein D (ApoD) In Human Serum As Marker Of Parkinson's Disease

Detection of Apolipoprotein D (ApoD) in Human Serum as Marker of Parkinson's Disease

Status
Unknown
Phase
Study type
Observational
Enrollment
180 (actual)
Sponsor
Privatklinik Villa Melitta · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Accepted

Summary

In Italy affected people are 200,000 and every year Parkinson new cases are 10,000. Aging is the principle risk factor of Parkinson with the possibility of its development doubling every five years after 65. Because of the increase of the social longevity and aging as the main risk factor, there are many repercussions on the health system (hospital stays and pharmaceutical costs) as on the social system (assistance- related problems). Parkinson's disease exerts an extremely negative impact on life's quality of the patient. In fact, because of Parkinson symptoms (tremor, dribble, etc), patient's social life will be reduced with the consequent development of the depression. Consequently, the early detection and treatment of Parkinson's is necessary. To achieve this goal, Apolipoprotein D (ApoD) in human serum as a marker of the oxidative stress-inflammation vicious cycle seems most promising candidate for diagnosis.

Detailed description

Total participants: n=180. Study Part 1: Health persons: n=90; Groups of health persons: n=3; Subjects per group: n=30. Study Part 2: Patients: n=90; Groups of patients: n=3; Subjects per group: n=30.

Conditions

Timeline

Start date
2011-11-01
Primary completion
2013-06-01
Completion
2013-11-01
First posted
2011-11-09
Last updated
2013-10-30
Results posted
2013-08-16

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT01467960. Inclusion in this directory is not an endorsement.